Jun 15, 2020
Emmes Announces Its Work on a Phase 3 Clinical Trial for Breakthrough Therapy Designation Product
May 07, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Fast Track Designation by the US FDA, Marking Another Milestone in Its Development
May 04, 2020
Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia
Dec 10, 2019
Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"
Nov 14, 2019
Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting
Oct 02, 2019
Cepheid Receives FDA Clearance for Xpert® BCR-ABL Ultra Test
Jul 21, 2019
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
May 27, 2019
Leukemia Therapeutics Market Worth $17.1 Billion by 2024 - Exclusive Report by MarketsandMarkets(TM)
Dec 05, 2018
PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program
Dec 03, 2018
Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting
Nov 21, 2018
Ascentage Pharma to Present New Clinical Data at the ASH 2018 Annual Meeting
Nov 01, 2018
Global Chronic Myeloid Leukemia Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares
Sep 04, 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna®(nilotinib)
Aug 14, 2018
Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
Jul 24, 2018
China Imatinib Market Report 2018-2022: Basic Concepts, Sales, Major Manufacturers, Prices & Market Prospects
Jun 02, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
May 17, 2018
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
Mar 22, 2018
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
Feb 16, 2018
Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline
Dec 22, 2017
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response